Mechanistic Insights into Protein Stability and Self-aggregation in GLUT1 Genetic Variants Causing GLUT1-Deficiency Syndrome

Mobeen Raja1,2 · Rolf K. H. Kinne1

Received: 19 October 2019 / Accepted: 14 January 2020 / Published online: 5 February 2020
© The Author(s) 2020

Abstract
Human sodium-independent glucose cotransporter 1 (hGLUT1) has been studied for its tetramerization and multimerization at the cell surface. Homozygous or compound heterozygous mutations in hGLUT1 elicit GLUT1-deficiency syndrome (GLUT1-DS), a metabolic disorder, which results in impaired glucose transport into the brain. The reduced cell surface expression or loss of function have been shown for some GLUT1 mutants. However, the mechanism by which deleterious mutations affect protein structure, conformational stability and GLUT1 oligomerization is not known and require investigation. In this review, we combined previous knowledge of GLUT1 mutations with hGLUT1 crystal structure to analyze native interactions and several natural single-point mutations. The modeling of native hGLUT1 structure confirmed the roles of native residues in forming a range of side-chain interactions. Interestingly, the modeled mutants pointed to the formation of a variety of non-native novel interactions, altering interaction networks and potentially eliciting protein misfolding. Self-aggregation of the last part of hGLUT1 was predicted using protein aggregation prediction tool. Furthermore, an increase in aggregation potential in the aggregation-prone regions was estimated for several mutants suggesting increased aggregation of misfolded protein. Protein stability change analysis predicted that GLUT1 mutant proteins are unstable. Combining GLUT1 oligomerization behavior with our modeling, aggregation prediction, and protein stability analyses, this work provides state-of-the-art view of GLUT1 genetic mutations that could destabilize native interactions, generate novel interactions, trigger protein misfolding, and enhance protein aggregation in a disease state.

Keywords Glucose transporter 1-deficiency syndrome · Sugar transport defect · Intermolecular interactions · Protein stability · Protein aggregation

Introduction
Genetic mutations affect protein folding by triggering aggregation, shifting conformational equilibria, or disrupting phase transitions. They can decrease the thermodynamic stability or at least disrupt protein folding pathways. Disease-associated alleles are more likely to target amino acids that stabilize the active and functionally folded form of a protein and therefore induce perturbed phenotypes of the protein with altered stability (Sahni et al. 2015). It has been long known that many human diseases are caused by genetic mutations that trigger protein misfolding and aggregation. The very first reported mutation (a glutamate to valine switch) found in hemoglobin β-chain was linked to trigger protein aggregation in sickle-cell anemia (Ingram 1957). Most common neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, or amyotrophic lateral sclerosis are thought to be linked with protein aggregations (Valastyan and Lindquist 2014). However, our understanding of the precise cause of such diseases remains unclear. Yet, the physiological roles of many aggregating proteins, including prion protein, α-synuclein, or amyloid beta are still unknown (Bendor et al. 2013; Castle and Gill 2017).
Membrane proteins have a tendency of structural transition of their polypeptide chains into aggregation-prone conformation in a lipid bilayer (Gorbenko and Trusova 2011). In this regard, hydrogen-bonding, electrostatic, and hydrophobic interactions play major roles in initiating and modulating the protein misfolding and aggregation. However, mutations can disrupt important interactions or generate novel but redundant interactions by linking other parts of the interaction network together. Such changes can result in loss of all interactions upon protein misfolding, leading to protein degradation (Sahni et al. 2015; Zhong et al. 2009).

Inactivating or loss-of-function (LOF) mutations of major facilitated diffusion glucose transporter 1 (GLUT1) lead to GLUT1-deficiency syndrome (GLUT1-DS), an autosomal dominant haploinsufficiency disorder, which results in a low glucose concentration in the cerebrospinal fluid and therefore lack of energy supply to the brain (Rotstein et al. 2010; De Vivo et al. 1991). The symptoms of GLUT1-DS include early-onset drug-resistant seizures, mild-to-severe developmental delay, and an acquired microcephaly. A wide range of LOF mutations, including multiple deletions, missense, and frame shift mutations, lead to either loss of GLUT1 function or disappearance at the cell surface in the GLUT1 has been demonstrated in hundreds of patients causing an early-onset and more severe symptoms (De Vivo et al. 1991; Wang et al. 2005; Klepper and Leideendecker 2007). However, the mechanism by which GLUT1 mutations could lead to the failure of a protein to remain in its native functional conformational state, and whether LOF mutations trigger protein misfolding or even aggregation is not known.

Considering the pathophysiological relevance, GLUT1 has been a major focus for structural and functional studies over the last few decades (Hediger et al. 2013; Shi 2013). Elevated expression levels of GLUT1 have been reported in several cancer types, making GLUT1 as an important predictive marker for tumorigenesis (Ramani et al. 2013; Kaira et al. 2014). The major breakthrough by advances in crystallography happened when the crystal structure of hGLUT1 has been resolved at 3.2 Å resolution by introducing two mutations N45T and E329Q in the full-length GLUT1 (Deng et al. 2014). Later, the full-length hGLUT1 was co-crystallized with inhibitors and captured in an inward-open conformation at a resolution of 2.9–3.0 Å (Kapoor et al. 2016). These structures not only provided a clear model for substrate interaction with residues in the sugar binding pocket but also defined the inhibitor binding pocket in the central sugar binding site.

The crystal structure of hGLUT1 now allows more precise mapping and mechanistic elucidation of disease-associated mutations in GLUT1. In this study, we examined the hGLUT1 crystal structure to investigate multiple amino acids that constitute hotspots of genetic mutations causing GLUT1-DS. The native interactions were modeled to confirm their roles in stabilizing the transporter conformation and function. The modeling of mutant side chains was carried out to examine packing of introduced residues in the local environment and to predict novel or non-native redundant interactions in TM regions or cytosolic ICH domain. Protein aggregation prediction tools (PASTA and DeepDDG servers) were utilized to construct aggregation free energy profiles of wild-type hGLUT1 and its mutants. These analyses set future studies to examine at a molecular level how GLUT1 mutants causing GLUT1-DS could trigger unfavorable protein folding, increasing protein aggregation and ultimately causing sugar transport defects.

Materials and Methods

Analysis of Genetic Variations for Identification of Native and Redundant Interactions

For detection of native and non-native interactions, the crystal structure of hGLUT1 (PDB ID: 5EQ1) was analyzed using PyMol modeling program (https://pymol.org/2/). Several natural missense mutations (N34S, S66F, G76D, G91D, R126H/L, E146K, L156R/N, R218H, K256V, T310I, or R333W), caused by single-nucleotide polymorphism (SNP), were specifically chosen for modeling of hGLUT1 (Fig. 1). Other mutations (i.e., addition or deletion mutations) were not feasible to predict confirmation/stability of the whole carrier using hGLUT1 PDB file. As shown in Fig. 1, the residues G91, E146, L156, R218, K256, and R333 are clustered on the intracellular side mainly within the large ICH domain of the transporter, whereas N34, S66, R126, E299, and T310 are positioned on the extracellular or TM regions. In PyMol, the distance (Å) between the donor–acceptor groups in PyMol were measured using ‘measurement’ tool. For demonstration purposes, SI-Fig. 1 represents bond lengths (dotted lines) and distances (Å) for some residues, e.g., R126 (A), T310 (B), S66 (C), and G76D (D), to depict interactions among reactive groups in PyMol. The strengths of H-bonding (weak, moderate, or strong) were classified by the measured distances. The distance of 2.2–2.5 Å between the two side chains were considered strong, 2.5–3.2 Å as moderate, and 3.2–4.0 Å as weak interaction (Jeffrey 1997). For clarity and to avoid extensive labeling, all modeling figures were prepared without showing the measured bond distances that are compiled in Table 1. Mutagenesis tool was selected to introduce mutagenic residues and to depict the novel interactions among the donor–acceptor groups as described previously (Raja and Kinne 2012). The CaPTURE program was run (http://capture.caltech.edu/) using PDB ID: 5EQ1 to identify energetically significant cation–pi interactions within WT-hGLUT1 (Gallivan and Dougherty 1999).
**Table 1** Summary of mutations and interaction partners exhibiting native or novel interactions

| Mutation (SNPs) | Interacting amino acid | Measured distance (Å) | Interaction/H-bond | Type of interaction |
|----------------|------------------------|-----------------------|--------------------|--------------------|
| N34S           | N34–S294               | 2.0                   | Strong H-bond      | Native/non-covalent |
|                | N34–T295               | >4.0                  | Weak H-bond        | Native/non-covalent |
|                | N34–T310               | 3.4                   | Weak H-bond        | Native/non-covalent |
| S66F           | S66–Q422               | 2.6                   | Moderate H-bond    | Native/non-covalent |
|                | S66F–M420              | –                     | Packing defect     | –                  |
| G76D           | G76D–W412              | 1.7                   | Anion–quadrupole   | Redundant/non-covalent |
| G91D           | G91D–F213              | 2.9                   | Anion–quadrupole   | Redundant/non-covalent |
| R126H          | R126–N29               | 2.0                   | Strong/covalent    | Native              |
|                | R126–S68               | 2.2                   | Strong/covalent    | Native              |
| R126L          | R126L–I33              | 3.8                   | Hydrophobic        | Redundant/non-covalent |
| E146K          | E146–R92               | 2.1                   | Strong electrostatic| Native/non-covalent |
|                | E146K–F213             | 3.3                   | Cation–πi          | Redundant/non-covalent |
| L156R          | L156R                  | –                     | Packing defect     | –                  |
| L156N          | L156N–S148             | –                     | H-bond*            | Redundant/non-covalent |
| R218H          | R218–E220              | 2.4                   | Strong electrostatic| Native/non-covalent |
|                | R218H–F213             | 2.1                   | NH–πi              | Redundant/non-covalent |
| K256V          | K256V–P401             | 3.6                   | Hydrophobic        | Redundant/non-covalent |
| E299K          | E299–K38               | 1.9                   | Strong electrostatic| Native/non-covalent |
| T310I          | T310–N34               | 3.4                   | Weak H-bond        | Native/non-covalent |
|                | T310–Q172              | 3.3                   | Weak H-bond        | Native/non-covalent |
| R333W          | R333–E329              | >4.0*                 | Flexible region*   | Native/non-covalent |
|                | R333W–F389             | 3.1                   | pi–πi              | Redundant/non-covalent |

*Refers to the positioning of amino acids in dynamic loop which can change its position upon formation of interaction pairs.

**Fig. 1** Three-dimensional structure of human GLUT1 (PDB ID: 5EQI) in the membrane plane depicting the positions of LOF pathogenic genetic mutations triggering GLUT-DS. The positions of intracellular helices (ICH) and several natural mutations (N34S, S66F, G76D, G91D, R126H/L, E146K, L156R/N, R218H, K256V, T310I, or R333W) in ball-and-stick model are highlighted. The structure was analyzed in a PyMol computer modeling program (http://www.pymol.org). For clarity, two side views (a and b) are shown to depict the positions of genetic mutations with regard to the membrane plane (highlighted in light green).
Prediction of Protein Self-aggregation and Stability

The PASTA 2.0 server (http://protein.bio.unipd.it/pasta2/) predicts aggregation regions from protein sequences using a pairwise energy potential (Walsh et al. 2014). Amino acid sequences in FASTA format were used for prediction of self-aggregation in wild-type (WT)-GLUT1 and its genetic variants. The ‘mutate’ function was used to introduce single-point mutations and their effects on the aggregation ability of each protein sequence. As recommended by the server, energy threshold or cut-off was set to −5 to produce 95% specificity of the server. The server predicted aggregation in energy units where 1 PASTA Energy Unit (PEU) was equivalent to 1.192 kcal/mol. The server computed the best aggregation pairing energy and the aggregating residues were assigned as parallel aggregating (P). The probability profiles and pairings (of aggregates) were calculated for positions of amino acids where k and m represent first and second amino acid in a pair, respectively. Linear probability profiles were also calculated by the server comparing aggregation and helix profile or aggregation and disorder profile as a function of the residue position or number (k).

More recently developed DeepDDG server (http://protein.bio.unipd.it/ddg.html), a neural network-based method (Cao et al. 2019), was used to predict the stability change of GLUT1 mutant proteins. This method predicts protein stability based on the solvent accessible surface area of the mutated residues as well as buried hydrophobic areas. As input file, PDB ID (5EQI) for hGLUT1 was provided and DeepDDG as network model was selected. Point mutations were entered to calculate the differences between Gibbs free energy (ΔΔG) of WT and mutant in order to predict the stability of GLUT1 mutants (kcal/mol), where predicted ΔΔG value > 0 represents stable mutant, and value < 0 an unstable mutant protein.

Results

Human GLUT1 protein has been extensively studied biochemically and biophysically to understand its structure and function relationship (Hruz and Mueckler 2001; Mueckler et al. 1985). Similar to other major facilitator superfamily (MFS) transporters, GLUT1 was also considered to transport sugar as substrate by a mechanism similar to sodium-dependent glucose cotransporter (SGLT) family where substrate-binding site is alternately accessible from either side of the membrane through conformational changes of the transporters. Earlier investigations revealed that SLC2A1 gene provides instruction for generating human GLUT1 protein consisting of 493 amino acids (Fukumoto et al. 1988). Sequence analysis combined with mutagenesis, topology studies, and the crystal structure illustrated that GLUT1 comprises 12 transmembrane (TM) alpha-helical domains (Fig. 1) that are linked by extra- and intracellular loops with both N- and C-termini facing the cytosol (Hruz and Mueckler 2001; Mueckler et al. 1985; Kapoor et al. 2016). The crystal structures of hGLUT1 as well as xylose transporter XyLE from Escherichia coli authenticated several previously described biochemical findings that indicated the crucial roles of residues Q161, R126, Q279, Q282, N317, T321, W65, W388, W412, and V165 for glucose transport activity (Salas-Burgos et al. 2004; Olowski et al. 2000; Seatter et al. 1998). In addition, hGLUT1 structure confirmed the previous finding that the central channel is composed of TM helices 2, 4, 5, 7, 8, and 10. The internal segment of the transport pathway is lined by both hydrophilic and hydrophobic amino acids that provides perfect interaction for the glucose molecule. The highly conserved intracellular helices IC1, 2, 3, and 4, collectively called intracellular helices (ICH), in GLUT family interact with the cytosolic parts of the transmembrane domains mediating the inter-domain interactions (Deng et al. 2014; Kapoor et al. 2016).

Most GLUT1-DS causing mutations target polar or charged amino acids, which seem to have both structural and functional roles in stabilizing the transporter (Deng et al. 2014). Mutations close to or within the substrate-binding domain have been proposed to trigger reduced recognition of D-glucose and strikingly compromised transport activity (Sun et al. 2012; Madej et al. 2014). However, how genetic mutations, especially the ones that are located away from the transport pathway or localized in the cytosolic domains, disrupt the structural integrity of GLUT1 causing total loss of function is not well known.

N34S, T310I, and S66F Mutations in Destabilization of Intermolecular Interactions

The missense N34S mutation due to SNP (280A>G) in exon II was reported in 2005 for the first time in two patients with GLUT1 deficiency syndrome (Wang et al. 2005). In the crystal structure of GLUT1, N34 is located on membrane localized topological domain linking TM1 and TM1e (Kapoor et al. 2016), where it was shown to organize the outer face of GLUT1 via H-bonding to S294 and T295 on TM7 and T310 on TM8 (Fig. 2a). The N34S mutation replaces asparagine, which is amino double polar amino acid, and adds single hydroxyl group of serine (an uncharged amino acid), hence destabilizing the organization center and exhibiting ~55% of WT glucose uptake activity (Wang et al. 2005). Table 1 illustrates the measured distances between the two side chains. In addition, the strength of H-bonds and type of interaction are summarized based on the distance between the donor–acceptor groups.

Next, we modeled T310I missense mutation which is involved in H-bonding to N34 within the same organizing
center as described above. T310I is caused by a single-
nucleotide mutation at 929 nucleotide position in exon VII
(Klepper et al. 1999a). This mutation switches threonine to
a bulky isoleucine and triggers sugar transport defect exhib-
itng 53% of WT-GLUT1 glucose uptake activity, but not
trafficking defect, as studied by quantification of immuno-
reactive GLUT1 protein in erythrocyte membranes (Klepper
et al. 1999b; Iserovich et al. 2002).

In the crystal structure, T310 is located on the extracel-
lular side of the putative transport path (Fig. 2b) where it
forms H-bonds with N34 and Q172 located on TM6 (Kapoor
et al. 2016), as described above. An extended motif of ser-
ine/threonine hydroxyl groups has been shown to be impor-
tant for oligomerization or helix–helix interactions (Dawson
et al. 2002). Furthermore, mutation of T310 to a non-polar
isoleucine would result in an increase in bulk affecting the
packing of residues around the TM6 and TM8 and causing
sugar transport defect. These notions are well supported by
previous mutagenesis and functional studies revealing that
the size and hydrophilicity of the side chain at position 310
(T310) are crucial in GLUT1 structure and function (Wang
et al. 2003).

S66F mutation, an autosomal dominant mutation in exon
III, is caused by SNP at position 227 (Tzadok et al. 2014).
G76 is embedded in the TM2 which is positioned along the
transport pathway (Fig. 2d, left side). Substitution of gly-
cine (a particularly small, hydrophobic and neutral amino
acid) to aspartate (a long, hydrophilic and negatively charged
amino acid) has not been investigated for its adverse effects
on GLUT1 transport function. However, the patient with this
mutation was diagnosed with GLUT1-DS after exhibiting
reduction in myoclonic absence seizures during a short fast-
ing period related to a febrile seizures (Tzadok et al. 2014).
The modeling of GLUT1 structure suggests that G76 is not
a part of other transmembrane helices as its side chain is not
energetically close enough to H-bond to another residue in
the neighboring helix (e.g., TM11). However, G76D muta-
tion (Fig. 2d, right side) would result in increase in bulk and
further formation of strong, however, redundant anion–quad-
rupole interaction between aspartate 76 and tryptophan 412
located on TM11 (Table 1). Such H-bonding interactions

G76D and G91D Mutations Involved in Redundant
Interactions

The genetic mutation G76D, a de novo mutation in exon
III, is caused by SNP at position 227 (Tzadok et al. 2014).
G76 is embedded in the TM2 which is positioned along the
transport pathway (Fig. 2d, left side). Substitution of gly-
cine (a particularly small, hydrophobic and neutral amino
acid) to aspartate (a long, hydrophilic and negatively charged
amino acid) has not been investigated for its adverse effects
on GLUT1 transport function. However, the patient with this
mutation was diagnosed with GLUT1-DS after exhibiting
reduction in myoclonic absence seizures during a short fast-
ing period related to a febrile seizures (Tzadok et al. 2014).
The modeling of GLUT1 structure suggests that G76 is not
a part of other transmembrane helices as its side chain is not
energetically close enough to H-bond to another residue in
the neighboring helix (e.g., TM11). However, G76D muta-
tion (Fig. 2d, right side) would result in increase in bulk and
further formation of strong, however, redundant anion–quad-
rupole interaction between aspartate 76 and tryptophan 412
located on TM11 (Table 1). Such H-bonding interactions

S66F mutation, an autosomal dominant mutation in exon
III, is caused by substitution of serine with phenylalanine
(Klepper et al. 1999b). S66, located on TM2, is in proximity
to Q422 in TM11 and can favor a moderate H-bond forma-
tion between serine’s hydroxyl and glutamine’s amino group
(Fig. 2c, Table 1). The crystal structure and modeling indi-
cate that S66F mutation may not only perturbs helix–helix
interaction by destabilizing S66-Q422 H-bond but also could
interfere with the packing of TM2 and TM11 due to bulky
nature of phenylalanine ring. Such modification in protein
structure does not interfere with protein expression and/or
targeting to the cell surface, however; a significantly reduced
membrane association and an impaired glucose transport
(45% of wild-type glucose uptake activity) explains the
effect of structural instability (Klepper et al. 1999b).
are known to exist between certain anions (aspartate, glutamate, and phosphate) and aromatic amino acids (tryptophan, tyrosine, and phenylalanine) rings in protein–protein interfaces and membrane proteins (Chakravarty et al. 2018) with tryptophan exhibiting the highest tendency for this type of interaction.

G91D mutation is caused by SNP at nucleotide position 272 (GGC → GAC) in exon IV (Klepper et al. 2001). It is located on the loop linking TM2 and TM3 on the intracellular side where it does not seem to be involved in interaction with other residues (Fig. 2e, left side). According to the modeling, the side chain of G91D is located quite close to another negatively charged E209 that could trigger electrostatic repulsion (Fig. 2e, right side). This repulsion would be expected to bring G91D in a proximity to phenylalanine 213, which is located on IC1, to form redundant anion–quadrupole interaction between G91D and F213 (Table 1), similar to the effect described above for G76D mutation.

R126H/L and L156R/N Mutations in Destabilizing Structure and Establishing Redundant Interactions

Both R126H and R126L mutations are caused by SNP in exon IV (Brockmann et al. 2001; Wang et al. 2000; Pascual et al. 2002) R126H, caused by SNP (556G>A), was reported in five patients and transport studies showed ~57% of WT-GLUT1 glucose uptake activity, further illustrating that the charge at this position is important in facilitation of glucose transport (Brockmann et al. 2001; Pascual et al. 2002). According to 3D-structure, R126 is located away from the transport path and buried in TM4 where it strongly interacts with the amino group of N26 and backbone of S68 in the adjacent TM1 and TM2, respectively (Fig. 3a, Table 1). Exchange of R126 by charged histidine would remove strong H-bonds and introduce aromatic imidazole causing an increase in bulk in the adjacent TM2 where aromatic W65 and F72 are localized.

For R126L mutation (Wang et al. 2000), the substituted hydrophobic leucine seems to be positioned in the vicinity of another hydrophobic residue I33 in helix 1 (Fig. 4a). This could favor hydrophobic cluster formation among R126L, I33, V69, and I71. Such situation may alter helix–helix interaction and protein folding thereby impairing GLUT1 targeting (20% of native GLUT1) to the plasma membrane (Brockmann et al. 2001; Wang et al. 2000; Pascual et al. 2002). Furthermore, using 3-O-methyl-D-glucose as substrate of *Xenopus* oocytes, only 3.2% uptake was observed by the R126L mutant (Pascual et al. 2008).

L156R and L156N are novel mutations caused by SNP in exon IV (Tzadok et al. 2014). This mutant has not been

---

Fig. 3  **a** Interaction of R126 (TM4) with N29 and S68 in TM1 and TM2, respectively. R126H may alter the conformational stability of TM4 and TM2. For R126L mutation, the introduced hydrophobic leucine may interact with another hydrophobic residues or may involve cluster formation via interaction between R126L, I71, and I33. **b** Modeling of L156, L156R, or L156N. In particular, L156N may cause conformational changes via L156N-S148 side-chain interaction. See Table 1
Mechanistic Insights into Protein Stability and Self-aggregation in GLUT1 Genetic Variants…

studied biochemically and yet the transport function of L156R/N carrying GLUT1 protein is unknown. However, the patient with GLUT1-DS exhibited daily morning prolonged absences, other neurologic deficits, mild mental retardation, and microcephaly (Tzadok et al. 2014). In GLUT1 structure, L156 is located in TM5 where it is a part of a hydrophobic cluster comprising several hydrophobic residues L152, L12, V144, and V16 (Fig. 3b). L156R/N causes significant change as it switches hydrophobic leucine to positively charged non-hydrophobic arginine or uncharged polar asparagine. The modeling suggests that L156R side chain does not interact with any other amino acid(s) to form salt bridge; however, the removal of hydrophobic leucine and introduction of bulky side chain of arginine may alter the packing of neighboring IC1, 2, or 3 that are believed to maintain a proper conformation of the transporter (Kapoor et al. 2016). L156N mutation could probably pull S148 (located on the unordered or flexible loop) side-chain OH group to form favorable H-bonding. This redundant interaction could therefore cause a conformational change in this area, including IC1, 2, and 3, leading to protein misfolding and transport defect.

Destabilizing Salt Bridges by E146K, R218H and R333W Mutations

Mutation E146K, caused by a SNP (GAA → AAA) in exon IV, is located on the intracellular side on TM4. Mutation of a negatively charged E146 to positively charged lysine leads to glucose transport defect (Wang et al. 2000). According to the crystal structure and our modeling, E146 is located quite close to R92 to establish strong electrostatic interaction between the oppositely charged side chains (Fig. 4a, Table 1), thereby stabilizing the conformation of GLUT1 in this region. However, E146K mutation removes this interaction and apparently establishes a redundant interaction between E146K and F213 (located on IC2) via cation–π interaction. Both cation–π (between cationic side chain of lysine/arginine and aromatic side chain of phenylalanine/tryptophan/tyrosine) and π–π interactions (between aromatic side chains) have been dictated by distance and angle between the reactive groups (Gallivan and Dougherty 1999). To validate whether cation–π interactions can be detected in GLUT1, the CaPTURE program was run. Only 3 energetically significant native cation–π interactions were predicted that involved pairs of Arg51/Phe119, Arg126/Phe72, and Arg333/Phe389 with E(electrostatic) between −1.30 and −1.10 kcal/mol and with E (van der Waals) between −1.75 and −1.30 kcal/mol. PyMol modeling was carried out for Arg126/Phe72 and Arg333/Phe389 to determine the location of interacting residues (SI-Fig. 2, A and B). Modeling depicts that the distances between the reactive groups of both Arg/Phe pairs are > 4.0 Å. However, close coupling of such pairs is quite possible to form cation–π interactions when GLUT1 undergoes conformational change during transport cycle (Deng et al. 2014; Kapoor et al. 2016). Considering that the CaPTURE program is only useful for known protein structures, cation–π interactions could not be predicted in E146K mutant, which seems to interact with F213.
Another missense mutation in GLUT1-DS is caused by SNP (653G>A) in exon V, causing arginine in position 218 to be replaced by histidine (R218H). It has been shown that R218H causing mild-to-severe symptomatic GLUT1-DS could be associated to the effect of either diverse epigenetic or modifier genes on GLUT1 protein function (Klepper et al. 2005). However, this mutation has not been characterized for protein mistrafficking or glucose transport defect.

R218 is located in cytoplasmic IC1 (between H6 and H7). The structure and modeling show that R218 is localized quite close to E220 (located on unstructured loop connecting IC1 and IC2) to form H-bond via strong ionic interaction (Table 1) stabilizing both ICs in their native states (Fig. 4b, left side). Replacing R218 by histidine introduces an aromatic imidazole ring removing strong electrostatic interaction. The introduced histidine is apparently localized in the vicinity to F213 within the same IC1 to form strong NH–pi bond between imidazole and benzene ring (Fig. 4b, right side). These kinds of interactions are known as T-shaped histidine–aromatic contacts that arise frequently among the amino acid side groups in proteins (Trachsel et al. 2015).

R333 is located on TM9 facing cytosol and forms ionic bond with E329 which is located on the loop preceding TM9 (Fig. 4c, right side). Missense mutation of R333 (R333W) to a non-polar tryptophan is due to a SNP (CGG → TGG) in exon VIII (Wang et al. 2000). This residue is highly conserved among members of the GLUT family and the MFS membrane transport proteins from Archaebacteria throughout humans (Wang et al. 2000). R333 is potentially involved in establishing the membrane topology of human GLUT1. However, R333W mutation causes severe defects in GLUT1 function thereby exhibiting only 43% of WT glucose uptake activity (Wang et al. 2005; Pascual et al. 2002). The importance of this position is conserved among other GLUT family members as a corresponding R380W mutation in GLUT9 leads to renal hypouricemia type-2 (Kawamura et al. 2011).

Removal of ionic interaction by R333W can destabilize the segment between TM8 and TM9 leading to improper conformation or misfolding. According to the modeling, R333W variant is positioned quite close to F389 which is located on TM10b (Fig. 4c, left side). This can favor redundant formation of tryptophan–phenylalanine pair via pi–pi interaction (Table 1) with face-to-face geometry. Such aromatic–aromatic interactions are known to exist in proteins and can significantly contribute to stabilize the protein conformation (Rammath et al. 2012; Cherumuttathu et al. 2009). The mutation R333W could have another possible effect due to the preferential positioning of the aromatic side chain of substituted tryptophan at the membrane–water interface (Özdirekcan et al. 2008), thereby altering the packing of TM9.

**K256V Mutation in Hydrophobic Interactions**

Missense mutation K256 is caused by SNP (945A>G) in exon VI (Pascual et al. 2002). Site-directed mutagenesis studies in *xenopus* oocytes revealed mild decrease in GLUT1 protein expression (~85% of native GLUT1) with no clinical symptoms and 12.7% decrease in 3-O-methyl-D-glucose (3-OMG) uptake by the K256V mutant (Rotstein et al. 2010). However, major changes were observed in red blood cell uptake. The patient’s 3-OMG RBC uptake was ~35% as compared to control (100%). The genetic analysis revealed compound heterozygosity due to two heterozygous missense mutations, K256V and R126L in exon VI and IV, respectively (Rotstein et al. 2010).

In the crystal structure, K256 is located in the loop preceding IC4, a part of long ICH. The side chain of K256 does not seem to H-bond to any amino acid as it points toward the central cavity of GLUT1 (Fig. 4d, top panel). Interestingly, the loop preceding IC4 carries K255 and K256 that could interact with the negatively charged lipids on the cytoplasmic side and help stabilize IC4 at the membrane surface, similar to what has been depicted in other membrane proteins and their interaction with the negatively charged lipids (Raja et al. 2007; Raja 2010). Replacing K256 by a hydrophobic valine could weaken IC4-lipid interaction causing a shift in the short IC4 positioning with respect to the membrane surface and altering protein conformation. Furthermore, introduction of valine at 256 position would increase the hydrophobicity of IC4 also via possible hydrophobic interaction with P401 (located on TM11) which is a part of hydrophobic cluster (V257, I259, L260, and L262) in this region (Fig. 4d, bottom panel).

**Effect of Genetic Mutation on Free Energy and Protein Aggregation Potential**

To support our modeling in prediction of novel interactions and protein misfolding, we used PASTA 2.0 server to detect protein aggregation in WT-GLUT1 and its genetic variants. The comparison of free energy profiles of full-length WT-GLUT1 and single mutants S66F, R126H, and R126L are shown in Fig. 5a. Compared to WT-GLUT1, lower energy (an increase in aggregation potential) of mutants was detected in the so-called aggregation-prone region 1 (APR1), as highlighted by the dotted lines. This region corresponds to residues ~50–150 that constitute TM2, 3, and 4. WT-GLUT1 exhibited lowest energy of ~14.2 kcal/mol of APR1. For mutants R126H, S66F, and R126L, aggregation potential of APR1 was increased due to a slight decrease in free energies by ~15.3, ~15.8, and ~16.3 kcal/mol, respectively. For mutants E299K, T310I, and R333W (Fig. 5b), an increase in aggregation potential was predicted in the other region, called aggregation-prone region 2 (APR2).
Mechanistic Insights into Protein Stability and Self-aggregation in GLUT1 Genetic Variants…

region (APR2), which corresponds to residues ~270–390 (or constitute TM7, 8, 9 and 10a). For WT-GLUT1, the best free energy of −14.5 kcal/mol was estimated for APR2. The mutants E299K, R333W, and T310I exhibited best aggregation energy of −15.1, −16.4, and −16.5, respectively. All other mutants did not exhibit any difference in free energy profile as compared to WT-GLUT1 (SI-Fig. 3).

Furthermore, the lowest energy was calculated for so-called aggregating region (AR), which was found to be similar among WT and all other mutants (Fig. 5a, b). This AR corresponds to residues 402–452 (highlighted in blue) as shown in the amino acid sequence of WT-GLUT1 (SI-Fig. 4). The prediction of parallel aggregates (P) and the probability of aggregation among pairs (denoted by k and m) are also represented. The helical prediction by PASTA 2.0 (TM1–TM12, highlighted in green) agrees well with GLUT1 structure and sequence. The pairing description of residues 402–452 for WT-GLUT1 is shown (SI-Fig. 5), illustrating the formation of 20 aggregates or pairing segments of varying sizes that occurred in the region between residues 402 and 452. The aggregation energy of AR (ranged between −18.6 to −21.2 kcal/mol) was found to be similar for WT and all mutants. The linear probabilities of aggregation vs. helix profile and aggregation vs. disorder profile were calculated, agreeing with the amino acid sequence-based aggregation prediction (SI-Fig. 6). In addition to identification of AR in all proteins, the aggregation prediction server also recognized aggregation-prone regions, such as APR1 and APR2. As predicted above, several genetic mutants exhibited minor differences in energy profiles as compared to WT that need to be taken into account when protein folding is significantly affected by small changes in the free energies (see “Discussion” section).

Using DeepDDG server, the ΔΔG values (kcal/mol) were found to be <0 for the following mutants: N34S (−0.586), S66F (−0.703), G76D (−2.625), G91D (−2.716), R126H (−1.861), E146K (−1.183), L156R (−1.280), R218H (−0.467), K256V (−0.632), T310I (−1.047), and R333W (−0.323), indicating unstable proteins, except for R126L (0.477) which probably behaved similar to WT. The predictions from both PASTA and DeepDDG programs indicate that genetic mutations destabilize the GLUT1 protein structure leading to unstable proteins or protein aggregation.

Discussion

Three general effects were considered in the present study: (1) side-chain interactions which could influence ligand binding, rigid carrier movements and small gate motions, (2) folding changes that can result in misfolding, and (3) aggregation potential which informs our understanding of intra and intermolecular domain interactions. Our structural
analyses of GLUT1 mutations not only predicted native stabilizing forces but also identified unique characteristics of mutated residues in establishing novel non-covalent interactions (especially hydrogen bonds, anion-quadrupole, cation–pi, NH–p, pi–pi, and hydrophobic interactions), thereby altering native GLUT1 structure and conformation. GLUT1 has been shown to undergo several functional conformational changes during transport cycle (Deng et al. 2014; Kapoor et al. 2016). Such transitioning can be energetically quite close to the native state of the transporter. However, LOF mutations may very well interfere with this equilibrium, leading to protein misfolding or significant loss of the active conformation (Hediger et al. 2013; Shi 2013; Deng et al. 2014).

Using theoretical prediction and simulation (Clementi and Plotkin 2004), it has been shown that in proteins non-native interactions exist, but they are too small to perturb the folding as compared to the large native interaction energies that drive native folding. If non-native interactions are increased to larger values, the folding rates are significantly decreased. Hence, the thermodynamic free energy barrier is lowered by the presence of non-native interactions triggering stable misfolded structures (Clementi and Plotkin 2004). There exists an energy gap between the native and any other potential conformations of a protein (Bryngelson et al. 1995; Karplus and Sali 1995), as observed among WT and some GLUT1 mutants in the APR1 or 2. Such gaps can be filled by native non-covalent interactions that could help stabilize the native conformation (Dill 1990). This is not possible when irreversible mutations destabilize crucial native interactions. In fact, we predicted that mutating residues in a protein not only destabilize the native conformation but also make the introduced incompatible residues interact with the neighboring residue and cause unfavorable non-local interactions in the tertiary structure, as summarized in Table 1. This step may be required when non-native conformation is urged to overcome an energy gap. However, such native-like redundant conformation may lead to a distinct or non-functional conformation.

A single mutation can significantly destabilize a protein by several kcal/mol, further lowering energy and leading to an unfolding or aggregation state (Tokuriki et al. 2008). Computational predictions have suggested that 20–50% of disease-causing mutations decrease protein stability (Berliner et al. 2014; Yue et al. 2005). In particular, it was estimated that ~20% of genetic variants destabilize proteins by over 1.5 kcal/mol. Such energy difference corresponds to almost tenfold increase in the ratio of unfolded to folded protein (Berliner et al. 2014). In line with this information, the free energy lowered by 1.5–2.5 kcal/mol (Fig. 5) points to an unfolding or rather misfolding tendency of the APR1 or 2 in GLUT1 mutants. Such aggregation-prone regions represent dynamic structures and may undergo significant conformational changes during transport cycle (Deng et al. 2014; Kapoor et al. 2016). Perhaps misfolding of such regions could also interfere with GLUT1 structure determination, where binding of inhibitors within glucose binding region (Kapoor et al. 2016) might stabilize the protein structure by eliciting stabilizing interactions, improving protein solubility and stability for crystallization studies.

According to the modeling, the mutation S66F located on TM2 could destabilize the interaction with Q422 by introducing bulky phenylalanine (Fig. 2c), leading to misfolding or packing defect of TM2 and potential aggregation of APR1 (representing TM2, 3, and 4). Similarly, R126L/H located on TM4 would destabilize the network of interactions, involving TM1 and 2, by introducing bulky histidine or hydrophobic valine, thereby increasing aggregation potential of APR1. The mutation T310I (located on TM8) not only destabilizes the organizing center of the transporter (Fig. 2b) but could also lead to misfolding or potential aggregation of APR2 (TM7, 8, 9, and 10a). Furthermore, R333W (located on TM9) would be expected to elicit novel interaction with F389 on TM10 (Fig. 4c) triggering unfavorable conformational change and further increasing the aggregation potential of APR2.

However, a word of caution is also necessary. No changes in aggregation free energy profiles were observed for mutants N34S, G76D, G91D, E146K, L156R/N, R218H, and K256V using PASTA. Perhaps such predictions are limited due to the approximations used in the underlying algorithm that were too large to assess the relevance of these single mutations. Another explanation is that not all mutations may necessarily elicit protein aggregation. The prediction of structural changes followed by novel redundant interactions could also stabilize the non-native conformation of the protein leading to either impaired protein assembly in the membrane, sugar uptake or both. Nevertheless, the predictions from PyMol and PASTA need to be combined with experimental data using site-directed mutagenesis to generate single-point and double mutants carrying genetic mutation and mutation of predicted interacting partner, as calculated in our analyses. These mutants should be expressed in a suitable host (e.g., HEK cells or Xenopus oocytes) to determine their expression levels, transport activities, protein oligomerization, and aggregation detection based on size exclusion chromatography of detergent solubilized GLUT1 proteins (Mueckler and Makepeace 2005; De Zutter et al. 2013), and sensitivities to substrates or inhibitors, e.g., cytochalasin B or phenylalanine amides.

The calculated aggregation free energy profiles do not take into account distinct protein folding in the membrane environment. Yet, qualitatively similar shapes of aggregation free energy profiles suggest that WT and GLUT1 mutants exist in thermodynamically unfavorable conformation. This agrees well with the notion that proteins containing intrinsically disordered regions, including the WT proteins, are
prone to misfolding (Qin et al. 2013). However, mutations further promote the aggregation of the protein. Hence, the phenotypic consequences of the mutations cannot be easily elucidated by the function of the WT protein, especially when the protein is known to exist in aggregates or oligomeric intermediates (De Zutter et al. 2013; Looyenga et al. 2016).

GLUT1 has been studied for its dimerization and tetramerization at the cell surface using GLUT1–GLUT3 chimeras. The tetramers were evaluated to have fourfold more catalytic activity than GLUT dimers suggesting that allosteric transport behavior is reflected by subunit interactions (De Zutter et al. 2013). This study also highlighted the roles of TM2, 5, 8, and 11 in GLUT1 dimerization, and TM9 in tetramerization. Interestingly, GLUT1 was later detected to behave as a multimeric complex in live cells where monomers were found to be initially associated via N-to-N-terminal dimers, which could then form tetramers stabilized by homomeric interactions between the adjacent C-termini of the four monomers (Looyenga et al. 2016). These studies suggest that tetramerization process is initiated via interaction between the cytosolic domains and the stability of these tetramers is further enhanced via TM intra-domain interaction. The multimerization of tetramers, which is different than dynamic aggregation of GLUT1 reported previously (Pascual et al. 2008), occurs most likely via cooperativity among tetramers of modestly expressed GLUT1, as depicted in the model shown in Fig. 6. In this regard, genetic mutations that destabilize native conformation and re-establish non-native interactions, as detected by our modeling and aggregation prediction analyses, could drastically affect the folding of intracellular helices (ICH) that interact with the cytosolic parts of the TM domains via extensive polar interactions (Deng et al. 2014; Kapoor et al. 2016). Because many mutations derived from GLUT1-DS map to residues that mediate the inter-domain interactions on the cytosolic side, the misfolding in this region may result in aggregation of GLUT1 subunits or misfolded oligomeric complexes. It is also possible that TM9, which is included in predicted aggregation-prone regions, could determine an initial aggregation of GLUT1 tetramers. However, genetic mutations might increase the aggregation potential by triggering redundant interactions, further destabilizing GLUT1 conformation (Qin et al. 2013).

In addition to GLUT1 tendency to aggregate as a function of GLUT1-DS mutation, we would also like to propose how genetic mutations could affect transport mechanism of monomeric GLUT1 mutants, when expressed at the cell surface. In this regard, at least two kinetic models (the simple carrier and the fixed-site carrier) can be considered. The simple carrier, which was proposed to alternate between exofacial and endofacial orientations (Vollers and Carruthers 2012), may not be able to bind sugar and undergo a conformational change in GLUT1-DS. For instance, mutations at positions N34 or T310 that could disorganize the outer face of GLUT1 leading to improper binding of sugar to the exofacial face and compromising sugar uptake. Significantly reduced membrane association of S66F mutant also points to the same effect. G76D and G91D would be considered to lock the transporter in a rather rigid conformation that is not flexible to allow alternating orientations. R126 and E146 mutations, located quite close to the outer and inner face of the transporter, respectively, would destabilize the meshwork of interactions leading to improper binding of sugar to both exofacial and endofacial faces of the transporter. Furthermore, mutations of R218, K256, and R333 would restrict the movement of intracellular IC1 and 2, impairing endofacial orientations and sugar translocation.

Considering the fixed-site carrier model (Vollers and Carruthers 2012), where GLUT1 simultaneously exposes endofacial and exofacial sugar binding sites and a large central cavity to allow exchange of bound sugar with cavity sugar (known as geminate exchange), mutation of N34, T310, or S66 would lead to improper binding of sugar to the exofacial face, thereby inhibiting geminate exchange and sugar translocation. Mutations of G76, G91, E146, and R218 would impair the flexibility of the carrier at the exofacial face thereby restricting the exchange of bound sugar with cavity sugar. R126 mutation would potentially lead to
improper binding of sugar to exofacial face. Mutations of R333 or K256 would also be expected to impair the geminate exchange and sugar translocation process.

This study investigates the structural consequences of GLUT1-DS mutations and their effects on function that may help us understand the structural basis of sugar transport. Lastly, GLUT1 mutants with a higher propensity to aggregate might exhibit stronger potential to partition into membranes and cause pathogenesis. The homeostasis of aggregated proteins may trigger sporadic and familial disease (Qin et al., 2013), similar to what has been described for many aggregated proteins in diseased states.

Acknowledgements Open access funding provided by Projekt DEAL.

Compliance with Ethical Standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Bendor JT, Logan TP, Edwards RH (2013) The function of α-synuclein. Neuron 79:1044–1066

Berliner N, Teyar J, Colak R, Garcia LS, Kim PM (2014) Combining structural modeling with ensemble machine learning to accurately predict protein fold stability and binding affinity effects upon mutation. PLoS ONE 9:e107353

Broeckmann K, Wang D, Korenke CG, von Moers A, Ho YY, Pascaul JM, Kuang K, Yang H, Ma L, Kranz-Eble P, Fischbarg J, Hanefeld F, De Vivo DC (2001) Autosomal dominant Glut-1 deficiency syndrome and familial epilepsy. Ann Neurol 50:476–485

Bryngelson JD, Onuchic JN, Socci ND, Wolynes PG (1995) Funnels, pathways and the energy landscape of protein folding: a synthesis. Proteins 21:167–195

Cao H, Wang J, He L, Qi Y, Zhang JZ (2019) DeepDDG: predicting the stability change of protein point mutations using neural networks. J Chem Inf Model 59(4):1508–1514

Castle AR, Gill AC (2017) Physiological functions of the cellular prion protein. Front Mol Biosci 4:19

Chakravarty S, Ung AR, Moore B, Shore J, Alshamrani M (2018) A comprehensive analysis of anion-quadrupole interactions in protein structures. Biochemistry 57(12):1852–1867

Cherumuttathu HS, Mohan N, Vijayalakshmi KP, George R, Mathew JM (2009) Typical aromatic noncovalent interactions in proteins: a theoretical study using phenylalanine. J Comp Chem 30:1392–1404

Clementi C, Plotkin SS (2004) The effects of nonnative interactions on protein folding rates: theory and simulation. Protein Sci 13(7):1750–1766

Dawson JP, Weinger JS, Engelman DM (2002) Motifs of serine and threonine can drive association of transmembrane helices. J Mol Biol 316:799–805

De Vivo DC, Trifiletti RR, Jacobson RJ, Ronen GM, Behmand RA, Harik SI (1991) Defective glucose transport across the blood–brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. New Eng J Med 325:703–709

De Zutter JK, Levine KB, Deng D, Carruthers A (2013) Sequence determinants of GLUT1 oligomerization: analysis by homology-scanning mutagenesis. J Biol Chem 288(28):20734–20744

Deng D, Xu C, Sun P, Wu J, Yan C, Hu M, Yan N (2014) Crystal structure of the human glucose transporter GLUT1. Nature 510(7503):121–125

Dill KA (1990) Dominant forces in protein folding. Biochemistry 29:7133–7155

Fukumoto H, Seino S, Imura H, Seino Y, Bell GI (1988) Characterization and expression of human HepG2/erythrocyte glucose-transporter gene. Diabetes 37:657–661

Gallivan JP, Dougherty DA (1999) Cation-π interactions in structural biology. Proc Natl Acad Sci USA 96(17):9459–9464

Gorbenko G, Trusova V (2011) Protein aggregation in a membrane environment. Adv Prot Chem Struct Biol 84:113–142

Hediger MA, Clemencon B, Burrier RE, Bruford EA (2013) The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med 34:95–107

Hruz PW, Mueckler MM (2001) Structural analysis of the GLUT1 facilitative glucose transporter (review). Mol Membr Biol 18:183–193

Ingram VM (1957) Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature 180:326–328

Iserovich P, Wang D, Ma L, Yang H, Zuniga FA, Pascaul JM, Kuang K, De Vivo DC, Fischbarg J (2002) Changes in glucose transport and water permeability resulting from the T310I pathogenic mutation in Glut1 are consistent with two transport channels per monomer. J Biol Chem 277:30991–30997

Jeffrey GA (1997) An introduction to hydrogen bonding. Oxford University Press, New York

Kaira K, Serizawa M, Koh Y, Takahashi T, Yamaguchi A, Hanaoka H, Oriuchi N, Endo M, Ohde Y, Nakajima T, Yamamoto N (2014) Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer. Lung Cancer 83(2):197–204

Kapoor K, Finer-Moore JS, Pedersen BP, Caboni L, Waight A, Hillig RC, Bringmann P, Heisler I, Müller T, Siebeneicher H, Stroud RM (2016) Mechanism of inhibition of human glucose transporter GLUT1 is conserved between cytochalasin B and phenylalanine amidites. Proc Natl Acad Sci USA 113(17):4711–4716

Karplus M, Sali A (1995) Theoretical studies of protein folding and unfolding. Curr Opin Struct Biol 5:58–73

Kawamura Y, Matsuo H, Chiba T, Nagamori S, Nakayama A, Inoue H, Utsumi Y, Oda T, Nishiyama J, Kanai Y, Shinomiya N (2011) Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleoside Nucleotide Nucl Acids 30:1105–1111

Klepper J, Leendecker B (2007) GLUT1 deficiency syndrome—2007 update. Dev Med Child Neurol 49:707–716

Klepper J, Garcia-Alvarez M, O’Driscoll KR, Parides MK, Wang D, Ho YY, De Vivo DC (1999a) Erythrocyte 3-O-methyl-D-glucose uptake assay for diagnosis of glucose-transporter-protein syndrome. J Clin Lab Anal 13:116–121
Klepper J, Wang D, Fischbarg J, Vera JC, Jarjour IT, O’Driscoll KR, De Vivo DC (1999b) Defective glucose transport across brain tissue barriers: a newly recognized neurological syndrome. Neurochem Res 24:587–594

Klepper J, Willemsen M, Verrrips A, Guertsens E, Herrmann R, Kutzick M, Florcken A, Voit T (2001) Autosomal dominant transmission of GLUT1 deficiency. Hum Mol Genet 10:63–68

Klepper J, Scheffer H, Leendekerker B, Gertsen E, Binder S, Leferink M, Hertzberg C, Nake A, Voit T, Willemsen MA (2005) Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 36:302–305

Looyenga B, VanOpsdall C, Lee Z, Bell J, Lodge E, Wrobel K, Arnoys E, Louters L (2016) Determination of GLUT1 oligomerization parameters using bioluminescent Förster Resonance Energy Transfer. Sci Rep 6:29130

Madej MG, Sun L, Yan N, Kaback HR (2014) Functional architecture of MFS-D glucose transporters. Proc Natl Acad Sci USA 111:E719–E727

Mueckler M, Makepeace C (2005) Cysteine-scanning mutagenesis and substituted cysteine accessibility analysis of transmembrane segment 4 of the Glu1 glucose transporter. J Biol Chem 280(47):39562–39568

Mueckler M, Caruso C, Baldwin SA, Panico M, Blench I, Morris HR, Allard WJ, Lienhard GE, Lodish HF (1985) Sequence and structure of a human glucose transporter. Science 229:941–945

Olsowski A, Monden I, Krause G, Keller K (2000) Cysteine-scanning mutagenesis of helices 2 and 7 in GLUT1 identifies an exofacial cleft in both transmembrane segments. Biochemistry 39:2469–2474

Özdirekcan S, Nyholm TKM, Raja M, Rijkers DTS, Liskamp RMJ, Olsowski A, Monden I, Krause G, Keller K (2000) Cysteine-scanning mutagenesis of helices 2 and 7 in GLUT1 identifies an exofacial cleft in both transmembrane segments. Biochemistry 39:2469–2474

Ozdiireccion S, Nyholm TKM, Raja M, Rijkers DTS, Liskamp RMJ, Killian JA (2008) Influence of trifluoroethanol on membrane interface anchoring interactions of transmembrane α-helical peptides. Biophys J 94:1315–1325

Pascual JM, Van Heerum RL, Wang D, Engelstad K, De Vivo DC (2002) Imaging the metabolic footprint of Glut1 deficiency on the brain. Ann Neurol 52:458–464

Pascual JM, Wang D, Yang R, Shi L, Yang H, De Vivo DC (2008) Structural signatures and membrane helix 4 in GLUT1: inferences from human blood-brain glucose transport mutants. J Biol Chem 283:16732–16742

Qin H, Lim L, Wei Y, Gupta G, Song J (2013) Resolving the paradox for protein aggregation diseases: a common mechanism for aggregated proteins to initially attack membranes without needing aggregates. Version 1. F1000Res. 2:221 (eCollection 2013)

Raja M (2010) The role of phosphatidic acid and cardiolipin in stability of the tetrameric assembly of potassium channel KcsA. J Membr Biol 234:235–240

Raja M, Kinne RKH (2012) Structural insights into genetic variants of Na+/glucose cotransporter SGLT1 causing glucose-galactose malabsorption: vSGLT as a model structure. Cell Biochem Biophys 63:151–158

Raja M, Spelbrink RE, de Kruijff B, Killian JA (2007) Phosphatidic acid plays a special role in stabilizing and folding of the tetrameric assembly of potassium channel KcsA. FEBS Lett 581:5715–5722

Rammohan P, Headford A, May MT (2013) GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch 462:203–209

Ramath A, Vaishnavi MK, Sherlin D, Kumar SP, Naveen K, Kanth PS, Sekar K (2012) Aromatic-aromatic interactions in structures of proteins and protein-DNA complexes: a study based on orientation and distance. Bioinformatics 8(24):1220–1224

Rotstein M, Engelstad BS, Yang H, Wang D, Levy B, Chung WK, De Vivo DC (2010) Glut1 deficiency: inheritance pattern determined by haploinsufficiency. Ann Neurol 68:955–958

Sahni N, Yi S, Taipale M, Fuxman BJI, Coulombe-Huntington J, Yang F, Peng J, Weile J, Karras GI, Wang Y (2015) Widespread macromolecular interaction perturbations in human genetic disorders. Cell 161:647–660

Salas-Burgos A, Isroovich P, Zuniga F, Vera JC, Fischbarg J (2004) Predicting the three-dimensional structure of the human facilitative glucose transporter glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 87:2990–2999

Seatter MJ, De la Rue SA, Porter LM, Gould GW (1998) QLS motif in transmembrane helix VII of the glucose transporter family interacts with the C-1 position of D-glucose and is involved in substrate selection at the exofacial binding site. Biochemistry 37:1322–1326

Shi Y (2013) Common folds and transport mechanisms of secondary active transporters. Annu Rev Biophys 42:51–72

Sun L, Zeng X, Yan C, Sun X, Gong X, Rao Y, Yan N (2012) Crystal structure of a bacterial homologue of glucose transporters GLUT1–4. Nature 490:361–366

Takizak N, Sticher F, Serrano L, Tawfish DS (2008) How protein stability and new functions trade off. PLoS Comput Biol 4:e1000002

Trachsel MA, Ottiger P, Frey HM, Pfaffen C, Bihlmeyer A, Klopper W, Leutwyler S (2015) Modeling the histidine-phenylalanine interaction: the NH–π hydrogen bond of imidazole benzene. J Phys Chem B 119(25):7778–7790

Tzakos M, Nissenkorn A, Porper K, Matot I, Marcus S, Anikster Y, Menascu S, Bercovich D, Ben Zeev B (2014) The many faces of Glut1 deficiency syndrome. J Child Neurol 29(3):349–359

Valastyan JS, Lindquist S (2014) Mechanisms of protein-folding diseases at a glance. Dis Model Mech 7:9–14

Vollers SS, Carruthers A (2012) Sequence determinants of GLUT1-mediated accelerated-exchange transport—analysis by homology-scanning mutagenesis. J Biol Chem 287(51):42533–42544

Walsh I, Seno F, Tosatto SCE, Trovato A (2014) PASTA 2.0: an improved server for protein aggregation prediction. Nucleic Acids Res 42:W301–W307

Wang D, Kranz-Eble P, De Vivo DC (2000) Mutational analysis of GLUT1 (SLC2A1) in Glut-1 deficiency syndrome. Hum Mutat 16:224–231

Wang D, Pascual JM, Isroovich P, Yang H, Ma L, Kuang K, Zuniga FA, Sun RP, Swaroop KM, Fischbarg J, De Vivo DC (2003) Functional studies of threonine 310 mutations in Glut 1: T310I is pathogenic, causing Glut1 deficiency. J Biol Chem 278(49):49015–49021

Wang D, Pascual JM, Yang H, Engelstad K, Jiang S, Sun RP, De Vivo DC (2005) Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 57:111–118

Yue P, Li Z, Moult J (2005) Loss of protein structure stability as a major causative factor in monogenic disease. J Mol Biol 353:459–473

Zhong Q, Simonis N, Li Q-R, Charloteaux B, Heuze F, Klitgord N, Tam S, Yu H, Venkatesan K, Mou D, Swearingen V, Yildirim MA, Yan H, Dricot A, Szeto D, Lin C, Hao T, Fan C, Milstein S, Dupuy D, Brasseur R, Hill DE, Cusick ME, Vidal M (2009) Edgetic perturbation models of human inherited disorders. Mol Syst Biol 5:321

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.